- Researchers evaluated the efficacy and safety of intravenous ketamine for treating suicidal and depressive symptoms during major depressive episodes.
- This meta-analysis synthesized data from 26 randomized clinical trials involving 1,166 patients receiving either ketamine or control interventions.
- Single infusions significantly reduced suicidal symptoms at 24 hours with a standardized mean difference of -0.69 (95% confidence interval, -0.98 to -0.40).
- The authors concluded that intravenous ketamine effectively reduces acute symptoms, though serious adverse events were unrelated to the treatment.
- Clinicians may consider ketamine for acute symptom management, but must acknowledge that long-term outcomes remain poorly established.
Rapid Stabilization Strategies for Acute Suicidal Ideation and Depression
Major depressive episodes complicated by suicidal ideation represent a critical psychiatric emergency requiring immediate clinical intervention to prevent self-harm. While traditional monoaminergic antidepressants remain the standard of care, their therapeutic lag of several weeks leaves a significant window of vulnerability for patients in crisis [1]. Consequently, there is an urgent need for rapid-acting agents that target the glutamatergic system, specifically N-methyl-D-aspartate (a primary excitatory neurotransmitter receptor in the brain) antagonists, to bridge this gap [2]. Previous research has explored various formulations, including intranasal esketamine and oral ketamine, with varying degrees of efficacy and durability [3, 4]. A single intravenous infusion of ketamine has demonstrated a significant reduction in suicidal symptoms at 24 hours (standardized mean difference, -0.69; 95% confidence interval, -0.98 to -0.40), providing a potential bridge during acute crises [5]. Clinicians must balance the need for rapid symptom resolution against concerns regarding safety, dosing frequency, and the longevity of the antisuicidal effect [6, 7].
Meta-Analysis Parameters and Patient Demographics
The researchers conducted a systematic review and meta-analysis of 26 randomized clinical trials to evaluate the efficacy of intravenous ketamine for psychiatric stabilization. The comprehensive search spanned several major medical databases, including PubMed, PsycInfo, Cochrane Library, and Embase, from their inception through November 7, 2025. This strategy captured a broad evidence base for clinical evaluation, resulting in a final study population of 1166 patients diagnosed with a major depressive episode. Within this cohort, 626 patients received intravenous ketamine while 540 patients served as controls. To ensure the integrity of the blinding process, control groups were administered either a saline solution or midazolam. Midazolam, a benzodiazepine, is frequently utilized as an active placebo in ketamine research because its sedative effects help mimic the dissociative sensations associated with ketamine infusion, thereby reducing the likelihood of participants or clinicians correctly identifying the intervention arm. The investigators synthesized the data using Hedges g standardized mean differences (a statistical measure used to compare the magnitude of effect across different assessment scales) and random-effects models (a statistical method that accounts for heterogeneity and variation between individual studies). The primary outcomes measured were changes in suicidal and depressive symptoms, alongside response and remission rates. Additionally, the analysis incorporated safety measures, specifically tracking adverse events and serious adverse events, to provide a comprehensive profile of the clinical utility and tolerability of the intervention for practicing physicians.
Temporal Dynamics of Symptom Relief
The meta-analysis identified a rapid onset of therapeutic action following a single intravenous ketamine infusion, which is critical for the management of acute psychiatric crises. Depressive symptoms showed significant reduction at 4 hours post-infusion, yielding a standardized mean difference (SMD) of -1.74 (95% CI, -2.43 to -1.06). This statistical measure indicates a substantial early response, meaning patients experience profound relief within hours rather than weeks. This clinical improvement persisted through the first day of treatment, as depressive symptoms showed significant reduction at 24 hours post-infusion (SMD, -1.15; 95% CI, -1.58 to -0.72). The durability of a single dose was observed over the subsequent week, although the magnitude of the effect size showed a gradual decline over time. Depressive symptoms showed significant reduction at 3 days post-infusion (SMD, -0.97; 95% CI, -1.73 to -0.20) and maintained a significant reduction at 1 week post-infusion (SMD, -0.89; 95% CI, -1.65 to -0.13). These findings suggest that a single administration provides a therapeutic window of at least seven days, offering clinicians a vital period for further stabilization and the initiation of longer-term maintenance therapies. For patients requiring more sustained symptom control, the researchers analyzed the impact of multiple administrations over a treatment course. Repeated infusions resulted in significant depressive symptom reduction at the end of treatment (SMD, -0.81; 95% CI, -1.16 to -0.46). This sustained efficacy is particularly relevant for the management of acute major depressive episodes, confirming that both single and repeated intravenous ketamine protocols provide rapid and measurable relief from depressive symptoms during the acute phase of illness.
Durability of Antisuicidal Effects
The meta-analysis highlights a distinct and rapid impact on suicidal ideation, which is often the most critical clinical priority in the emergency or inpatient setting. For suicidal symptoms, the researchers found that a single ketamine infusion resulted in significantly lower symptoms at 24 hours compared with controls (SMD, -0.69; 95% CI, -0.98 to -0.40). This effect size suggests that the intervention provides a meaningful reduction in self-harm risk within the first day of administration. Such rapid stabilization is particularly relevant for clinicians managing patients in acute crisis, as it may facilitate safer transitions between levels of care or provide a critical window for the initiation of comprehensive psychiatric support. Perhaps most notable for long-term discharge planning is the persistence of these effects beyond the immediate post-infusion period. The data indicate that the reduction in suicidal symptoms after a single infusion remained significant at 1 month (SMD, -0.70; 95% CI, -1.17 to -0.24). This sustained benefit at 30 days suggests that the biological response to ketamine may provide enough symptomatic relief to allow for more effective engagement in psychotherapy and other social interventions. Furthermore, the study examined the utility of multiple doses for patients with persistent ideation. Repeated ketamine infusions showed a reduction of suicidal symptoms at the end of treatment (SMD, -0.72; 95% CI, -1.00 to -0.43), confirming that a serial dosing protocol maintains a consistent therapeutic effect throughout the acute phase of treatment.
Safety Profile and Tolerability in Clinical Practice
For clinicians weighing the risks of off-label psychiatric interventions, the safety data from this meta-analysis of 26 randomized clinical trials provide a necessary framework for risk-benefit analysis. The researchers monitored 1166 total patients, including 626 who received intravenous ketamine, for both minor and severe complications. Serious adverse events, including hospitalizations and deaths, were reported during the study period but were determined to be unrelated to the interventions. This finding is particularly significant for physicians managing high-risk populations, as it suggests that the most severe outcomes observed were likely consequences of the underlying major depressive episode or other comorbid conditions rather than the pharmacological effects of the ketamine itself. The tolerability of the treatment was further characterized by the nature and duration of non-serious side effects. Common adverse events such as headache were transient and resolved during the trials, indicating that the physical burden of the infusion is generally short-lived. Because these symptoms did not persist beyond the immediate treatment window, the data suggest that intravenous ketamine is a manageable option for acute stabilization. While the authors emphasize that longer-term safety and efficacy outcomes are not yet well established, the current evidence indicates that both single and repeated infusions are efficacious and generally well-tolerated for patients in the acute phase of a major depressive episode.
References
1. Zarate CA, Singh J, Carlson PJ, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Archives of General Psychiatry. 2006. doi:10.1001/archpsyc.63.8.856
2. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. American Journal of Psychiatry. 2013. doi:10.1176/appi.ajp.2013.13030392
3. Silberbauer LR, Eggerstorfer B, Michenthaler P, et al. Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis.. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.120466
4. Sapkota A, Khurshid H, Qureshi IA, et al. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review. Cureus. 2021. doi:10.7759/cureus.17352
5. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.. JAMA psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0612
6. Jollant F, Colle R, Nguyen TML, et al. Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review. Therapeutic Advances in Psychopharmacology. 2023. doi:10.1177/20451253231151327
7. Walsh Z, Mollaahmetoğlu ÖM, Rootman JM, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021. doi:10.1192/bjo.2021.1061